As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.

ZTS shares are climbing with conviction. See what is driving the move here

This dynamic environment sets the stage for Zoetis Inc. (NYSE:ZTS) as it faces critical scrutiny from KeyBanc Capital Markets regarding its product lineup and market positioning.

Analyst Take On Zoetis

KeyBanc Capital Markets initiated coverage on Zoetis, with continued headwinds from the launch of its osteoarthritis (OA) pain mAb products, and increased competition in key franchises.

Also Read: Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

KeyBanc writes Zoetis to continue to face headwinds from its OA pain mAb products (Librela & Solensia), which have been the subject of heavy social ...